



CLINICAL EVALUATION OF THE EFFICACY OF A SKIN CARE PRODUCT IN IMPROVING SKIN CONDITIONS

WEEK 8 FINAL REPORT

June 19, 2023

SPONSOR: Telomeron, LLC
833 W South Boulder Rd Building B
Louisville, CO 80027

TEST PRODUCTS: Telomere DNA Protection

STUDY NUMBER: 22-090

PROJECT NUMBER: 1204112

RESEARCH STANDARD

The conduct of this study will comply with the International Conference of Harmonization Tripartite Guideline on Good Clinical Practice, including, but not limited to, applicable FDA and EU regulations/guidelines set forth in 21 CFR Parts 11, and 50 and standard practices of ALS.

TABLE OF CONTENTS

	Page
I. Summary of Results.....	4
II. Study Objective.....	8
III. Study Dates.....	8
IV. Testing Facility.....	8
V. Test Product.....	8
VI. Test Product Handling.....	8
VII. Adverse Events.....	9
VIII. Protocol Deviations.....	9
IX. Subject Demographics.....	10
Appendix A – Protocol.....	12
Appendix B – Raw Data.....	25

I. SUMMARY OF RESULTS

Under conditions of the study a total of 52 healthy female subjects, completed 8 weeks of the clinical study evaluating the effectiveness of Test Product: Telomere DNA Protection in improving skin conditions.

A. Skin Hydration by Corneometer

Note: Positive difference indicates an improvement in skin hydration.

Parameter	15 Minute	Week 4	Week 8
Mean Percent Difference from Baseline	69.96% $p \leq 0.001$	50.36% $p \leq 0.001$	52.03% $p \leq 0.001$
Percent of Subjects Improved	100.00% $p \leq 0.001$	100.00% $p \leq 0.001$	100.00% $p \leq 0.001$

Bold values indicate statistical significance ($p \leq 0.05$).

Clinical Findings:

- There was a statistically significant improvement in skin hydration from baseline at the 15 minute, week 4, and week 8 post-treatment intervals.
- A statistically significant number of subjects showed improvement in skin hydration from baseline 15 minute, week 4, and week 8 post-treatment intervals.

B. Skin Firmness by Cutometer (R0)

Note: Negative difference indicates an improvement in skin firmness.

Parameter	15 Minute	Week 4	Week 8
Mean Percent Difference from Baseline	-3.50% $p = 0.015$	-5.13% $p = 0.037$	-5.43% $p = 0.025$
Percent of Subjects Improved	63.46% NS	55.77% NS	59.62% NS

Bold values indicate statistical significance ($p \leq 0.05$).

Clinical Findings:

- There was a statistically significant improvement in skin firmness from baseline at the 15 minute, week 4, and week 8 post-treatment intervals.

C. Skin Elasticity by Cutometer (R2)

Note: Positive difference indicates an improvement in skin elasticity.

Parameter	15 Minute	Week 4	Week 8
Mean Percent Difference from Baseline	4.14% $p=0.017$	-7.10% $p=0.010$	-9.93% $p\leq 0.001$
Percent of Subjects Improved	65.38% NS	32.69% NS	25.00% NS

Bold values indicate statistical significance ($p \leq 0.05$).

Clinical Findings:

- There was a statistically significant improvement in skin elasticity from baseline at the 15 minute post-treatment interval.
- There was a statistically significant decrease in skin elasticity from baseline at the week 4 and week 8 post-treatment intervals.

D. Skin Barrier Function by TEWL (N=50)

Note: Negative difference indicates an improvement in skin barrier function.

Parameter	Untreated (Control)		Treated	
	15 Minute	24 Hour	15 Minute	24 Hour
Mean Percent Difference from Baseline	-1.97% NS	4.17% $p=0.043$	-40.44% $p\leq 0.001$	-29.92% $p\leq 0.001$
Percent of Subjects Improved	52.00% NS	32.00% NS	100.00% $p\leq 0.001$	100.00% $p\leq 0.001$

Bold values indicate statistical significance ($p \leq 0.05$).

Clinical Findings:

Untreated (Control) Site:

- There was a statistically significant decrease in skin barrier function from baseline at the 24-hour post-treatment intervals.

Treated Site:

- There was a statistically significant improvement in skin barrier function from baseline at the 15-minute and 24-hour post-treatment intervals.

Note: Negative difference indicates Test Product Site had better skin barrier function than Control (Untreated) Site.

Comparison (% Δ Treatment-% Δ Control)	Interval	Variation Mean %	p -value
Test Product-Control	15 minute	-38.47%	≤ 0.001
Test Product-Control	24-hour	-34.10%	≤ 0.001

Bold values indicate statistical significance ($p \leq 0.05$).

Clinical Findings:

- Test Product site had statistically significantly more improvement in skin barrier function than Control (Untreated) site when compared to baseline at the 15-minute and 24-hour post-treatment intervals.

E. Clinical Grading

Note: Negative difference indicates an improvement in skin appearance.

Parameter	Fine Lines and Wrinkles (Eye Area)		Skin Lifting (Eye Area)	
	Week 4	Week 8	Week 4	Week 8
Mean Percent Difference from Baseline	-3.19% <i>p</i> ≤0.001	-3.99% <i>p</i> ≤0.001	-1.66% <i>p</i> =0.002	-2.66% <i>p</i> ≤0.001
Percent of Subjects Improved	38.46% NS	48.08% NS	19.23% NS	30.77% NS

Bold values indicate statistical significance (*p* ≤ 0.05).

Clinical Findings:

- There was a statistically significant improvement in appearance of fine lines and wrinkles (eye area) and skin lifting (eye area) from baseline at the week 4 and week 8 post-treatment intervals.

F. Post-Treatment Questionnaires (15 Minute and 24 Hour)

Scale: Strongly Agree, Agree, Disagree, Strongly Disagree

Statement	% of Subjects with Favorable Responses	
	15 Minute	24 Hour
1. The serum is absorbed quickly.	100.00%	96.15%
2. I like the texture of the serum.	98.08%	96.15%
3. This serum has a pleasant smell.	96.15%	98.08%
4. My skin feels smoother.	88.46%	96.15%
5. My skin feels cooled.	88.46%	84.62%
6. My skin feels refreshed.	96.15%	96.15%
7. My skin feels relaxed.	88.46%	92.31%

Bold values indicate statistical significance (*p* ≤ 0.05).

G. Post-Treatment Questionnaire (Week 4 and Week 8)

Scale: Strongly Agree, Agree, Disagree, Strongly Disagree

Statement	% of Subjects with Favorable Responses	
	Week 4	Week 8
1. My skin looks brightened.	92.31%	84.62%
2. My skin feels more hydrated.	88.46%	80.77%
3. My skin looks more youthful.	86.54%	78.85%
4. My skin tone is more even.	80.77%	75.00%
5. My skin has less wrinkles.	69.23%	75.00%
6. My eyes are less puffy.	84.62%	78.85%
7. The serum is absorbed quickly.	92.31%	96.15%
8. I like the texture of the serum.	94.23%	92.31%
9. This serum has a pleasant smell.	100.00%	90.38%
10. My skin feels smoother.	94.23%	84.62%
11. My skin feels cooled.	92.31%	88.46%
12. My skin feels refreshed.	94.23%	92.31%
13. My skin feels relaxed.	88.46%	73.08%
14. Appearance of dark pigmentation around the eye area reduced.		75.00%

Bold values indicate statistical significance ($p \leq 0.05$).

II. OBJECTIVES

To evaluate the effectiveness of a skin care product to:

- Improve skin hydration / moisturization
- Improve skin barrier function
- Improve skin firmness
- Improve skin elasticity
- Improve appearance of skin lifting in the eye area
- Reduce appearance of fine lines and wrinkles in the eye area
- Consumer perception

III. STUDY DATES

The study began on March 13, 2023 and week 8 ended on May 16, 2023.

IV. TESTING FACILITY

ALS Beauty and Personal Care
3301 North 2nd Street
Phoenix, AZ 85012

Investigator: Rania Ibrahim

V. TEST PRODUCT

Test Product	Number of Samples	Date Received	Accession Number
Telomere DNA Protection	60	23 Nov 2022	1204112
	60	13 Apr 2023	

Supplemental Products:

1. Neutral Cleansing Bar Soap
2. Neutrogena Ultra Sheer Dry-Touch Sunscreen Broad Spectrum SPF 30

VI. TEST PRODUCT HANDLING

Test products that have been reviewed and approved for use by the Regulatory and Safety representatives of Telomere, LLC will be tested. A sufficient quantity of samples of the above test products to allow for 70 subjects to use for the entire study duration will be received from Telomeron, LLC prior to start of the study.

Upon arrival at ALS Beauty and Personal Care (ALS) the test product will be assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received, and tests requested. Each individual sample of the test

product will be weighed before and after use by the subject. This information will be recorded on the test product log-in form. Samples will be retained for a period of 30 days beyond submission of final report. Sample disposition will be conducted in compliance with appropriate federal, state and local ordinances.

Test Product Application Instructions - Forearm

Approximately 2 mg/cm² of product will be applied to its designated treatment site on each subject, determined by computer generated randomization code, with a finger cot and gently rubbed into the skin until absorbed.

Site A: Test Product - TEWL Maintenance

Site B: Untreated Control – TEWL Maintenance

Test Product Use Instructions - Face

After cleansed skin. Apply one pump of the test product around entire eye area twice a day (morning and evening).

VII. ADVERSE EVENTS

To date, no adverse events have been noted for the study.

VIII. PROTOCOL DEVIATIONS

1	Subject 19735 and 35485: not included in TEWL analysis due to test sites compromised.
2	Subject 3441: subject week 8 readings were taken 4 days outside ± 3 day window.

IX. SUBJECT DEMOGRAPHICS

A total of 52 healthy female subjects consented, enrolled, and completed the clinical study.

Table 1. Subject Demographics:

No.	Subject ID	Subject Initials	Age	Race	Fitzpatrick
1	18	RMJ	58	AA	VI
2	841	SLR	62	C	II
3	871	KAM	63	C	II
4	1440	JAD	50	C	II
5	1566	CJH	59	NA	II
6	2337	MMM	56	C	II
7	3441	JMB	65	C	II
8	3445	JLR	61	C	III
9	3894	LAW	60	H	III
10	4321	CVC	61	H	III
11	4988	SIC	59	C	II
12	5107	GMK	62	C	II
13	6217	JLP	45	C	II
14	6987	ABP	64	C	II
15	7102	SLS	56	C	II
16	7226	J-T	60	H	II
17	7767	VDC	63	H	II
18	14404	HAB	55	C	I
19	14578	PMM	62	C	I
20	15152	YVZ	52	C	II
21	18766	CPC	58	C	II
22	18949	PLB	55	C	II
23	19606	DMO	58	C	I
24	19674	OAW	64	C	II
25	19735	MDJ	58	H	III
26	22705	NBW	47	C	I
27	23348	JAC	64	C	II
28	23680	MCF	45	C	I
29	23758	SLB	57	C	III
30	23961	EMB	59	C	III
31	25078	T-H	52	C	V
32	26648	MPL	59	C	II
33	27773	DMB	60	C	II
34	27957	M-R	54	C	I
35	28936	LLT	61	C	I
36	28966	K-D	56	NA	IV
37	31089	SRD	46	C	I

No.	Subject ID	Subject Initials	Age	Race	Fitzpatrick
38	33822	BJF	64	C	III
39	33882	R-R	63	C	II
40	33907	J-G	60	C	II
41	33984	V-A	46	C	II
42	35485	SLD	55	C	II
43	35490	BNM	65	AA	V
44	35497	MMM	58	AA	V
45	37445	SAP	64	C	II
46	40044	T-G	48	C	III
47	40236	SLB	56	C	I
48	40355	JJT	52	C	II
49	40637	DMH	53	C	I
50	40809	JMH	61	C	II
51	41118	CLB	61	C	II
52	42601	JEK	63	C	II

AA=African American, C= Caucasian, H= Hispanic, NA= Native American

APPENDIX A

CLINICAL EVALUATION OF A SKIN CARE PRODUCT FOR EFFICACY IN IMPROVING SKIN CONDITIONS

Study Number: 22-090

Principal Investigator: Rania Ibrahim, Ph.D.

Sub-Investigator: Brochelle Yazzie, B.S.

Sub-Investigator: Erin Nordman, B.S.

Sub-Investigator: Jordan DeSantis, MHI

Testing Facility: ALS Beauty and Personal Care
3301 N. 2nd Street
Phoenix, AZ 85012
PH: 602 277 1154

Sponsor: Telomeron, LLC
833 W South Boulder Rd Building B
Louisville, CO 80027

RESEARCH STANDARD

The conduct of this study will comply with the International Conference of Harmonization Tripartite Guideline on Good Clinical Practice, including, but not limited to, applicable FDA and EU regulations/guidelines set forth in 21 CFR Parts 11, and 50 and standard practices of ALS.

I. OBJECTIVE

To evaluate the effectiveness of a skin care product to:

- Improve skin hydration / moisturization
- Improve skin barrier function
- Improve skin firmness
- Improve skin elasticity
- Improve appearance of skin lifting in the eye area
- Reduce appearance of fine lines and wrinkles in the eye area
- Consumer perception
-

II. TESTING FACILITY

ALS Beauty and Personal Care
3301 North 2nd Street
Phoenix, AZ 85012

Investigator: Rania Ibrahim, Ph.D.
PH: 602-277-1154

III. STUDY DURATION

The study will be completed within a 12-week period (approximate 5-day washout period and a 12-week product usage).

IV. STUDY DESIGN AND METHODS

Test Product

Telomere DNA Protection

Supplemental Products

1. Neutral Cleansing Bar Soap
2. Neutrogena Ultra Sheer Dry-Touch Sunscreen Broad Spectrum SPF 30

Test Product Handling

Test products that have been reviewed and approved for use by the Regulatory and Safety representatives of Telomere, LLC will be tested. A sufficient quantity of samples of the above test products to allow for 70 subjects to use for the entire study duration will be received from Telomeron, LLC prior to start of the study.

Upon arrival at ALS Beauty and Personal Care (ALS) the test product will be assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received, and tests requested. Each individual sample of the test product will be weighed before and after use by the subject. This information will be recorded on

the test product log-in form. Samples will be retained for a period of 30 days beyond submission of final report. Sample disposition will be conducted in compliance with appropriate federal, state and local ordinances.

Test Product Application Instructions - Forearm

Approximately 2 mg/cm² of product will be applied to its designated treatment site on each subject, determined by computer generated randomization code, with a finger cot and gently rubbed into the skin until absorbed.

Site A: Test Product - TEWL Maintenance

Site B: Untreated Control – TEWL Maintenance

Test Product Use Instructions - Face

After cleansed skin. Apply one pump of the test product around entire eye area twice a day (morning and evening).

V. INFORMED CONSENT FORM, PHOTOGRAPHY RELEASE FORM AND MEDICAL HISTORY FORM

Informed consent will be obtained from each volunteer prior to initiating the study describing reasons for the study, possible adverse effects, associated risks and potential benefits of the treatment and their limits of liability. Panelists will sign and date the informed consent document and a photography release form to indicate their authorization to proceed and acknowledge their understanding of the contents. Each subject will be assigned a permanent identification number and complete an extensive medical history form. These forms along with the signed consent forms will be available for inspection on the premises of ALS only. ²¹ CFR. Ch. I. Part 50, Subpart B.

VI. SUBJECT SELECTION

Panel selection will be accomplished by advertisements in local periodicals, community bulletin boards, phone solicitation, electronic media or any combination thereof. Individuals will be admitted to study at the discretion of the Investigator or his designee based on medical history and findings on the pre-study interview and examination.

1. Number of Subjects: Approximately 60 healthy subjects meeting inclusion/exclusion criteria listed below will be enrolled to complete the study with a minimum of 50 subjects.
2. Age: 45-65
3. Sex: Female
4. Race: 80% Caucasian, 20% Other Unrestricted
5. Skin Type: Unrestricted
6. Inclusion Criteria:
 - a. Individuals who, at baseline, are free of any dermatological or systemic disorder, which would interfere with the results, at the discretion of the Investigator.
 - b. Individuals in good general health.

- c. Individuals who complete a preliminary medical history.
- d. Individuals who will read, understand and sign an informed consent document and a photography release form.
- e. Individuals who will be able to cooperate with the Investigator and research staff, have the test product applied according to the protocol and complete the full course of the study.
- f. Individuals who are not currently participating in and have not participated in any study involving the same test sites (face and volar forearms) for the past 7 days.
- g. Individuals who will refrain from eating and drinking hot liquids for at least 30 minutes prior to scheduled instrument readings.
- h. Individuals who are willing to refrain from wetting, wiping, covering, and/or applying product to the test sites (volar surface of the forearms) between the baseline and 24-hour time points.
- i. Individuals who will refrain from using any other personal care products (i.e. lotions, creams, cleansers) on the test site (face and volar forearms) for the duration of the study with the exception of products provided by the testing facility.
- j. Individuals who will continue to use their current cosmetic products (foundation, blush, eyeshadow, etc.), as long as they do not contain anti-aging ingredients. ALS staff will review and confirm approved cosmetics. Subjects will refrain from introducing any new cosmetics during the course of the study.
- k. Individuals with visible sagging skin in the eye area (score 0.5-9 on a 10-point scale).
- l. Individuals with visible fine lines and wrinkles in the eye area (score 0.5-9 on a 10-point scale).
- m. Individuals who agree to refrain from sun tanning/bathing and prolonged exposure to sunlight (outdoors).
- n. Individuals who agree to apply the sponsor provided sunscreen to the test site a minimum of 15 minutes prior to sun exposure and to reapply every hour they remain outdoors (exposed to UV).

7. Exclusion Criteria:

- a. Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
- b. Individuals with an active (flaring) disease or chronic skin allergies (atopic dermatitis, eczema, psoriasis, acne), or had recently treated skin cancer (within the last 12 months).
- c. Individuals with a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara) and/or radiation that could interfere with or increase the risk on study participation.
- d. Individuals with damaged skin at or in close proximity to test sites (e.g., sunburn, tattoos, excessive hair, piercings, scars, or other disfigurements).
- e. Individuals who have any history, which, in the Investigator's opinion, indicates the potential for harm to the subject or could place the validity of the study in jeopardy.
- f. Individuals who have had any medical procedure, such as laser resurfacing, or plastic surgery to the test sites within the last 12 months.

- g. Individuals who are currently using or during the last 6 months have taken a systemic retinoid or used, Retin A, or other Rx/OTC Retinyl A, or other astringent derived products or alpha hydroxyl acid treatments for photo-aging and fine lines/wrinkles.
- h. Individuals who have been medically diagnosed with Type I Diabetes.
- i. Individuals who indicate that they are pregnant, planning a pregnancy or nursing.
- j. Individuals who have a known history of hypersensitivity to any cosmetics, personal care products, and/or fragrances.
- k. Individuals who are employees of ALS.

VII. EXPERIMENTAL TECHNIQUES

Bioinstrumental Method to Measure Water Content of Human Skin^{1-3.}

Changes in skin conductance, impedance or capacitance are used to study epidermal hydration in vivo. The measurement is made on the difference in dielectric constant; skin has a low dielectric constant, and water has a high dielectric constant of 81. When skin is hydrated, conductance and capacitance increases and impedance decreases. When measuring capacitance, the measuring capacitor shows changes in capacitance according to the moisture content of the tissue. A glass lamina separates the metallic tracks in the probe head from the skin in order to prevent current conduction in the tissue. An electric scatter field penetrates the skin during the measurement and the dielectricity is determined. When measuring conductance, the conducting properties of the very upper layers of the skin is measured in micro-Siemens (μS) when subjected to an alternating voltage. The probe head is composed of eight contact pins and a ventilating spacer, which reduces occlusion when applying the probe, and hence minimizing water accumulation in the skin by the probe.

Corneometer CM 825 (Courage and Khazaka, Germany) will be used to measure the electrical capacitance/hydration or conductance/hydration, respectively, of the skin. Three replicate measurements will be taken on designated test sites at each interval

Bioinstrumental Method to Measure Skin Barrier Function^{4,5}

Transepidermal water loss (TEWL) is a measure of skin barrier function. The evaporimeter probe has two sensors, which measures the vapor pressure gradient arising within the chamber and between the skin and the surrounding air.

TEWL will be measured using DermaLab Evaporimeter (Cortex Technology, Hadsund, Denmark). Decreases in TEWL post barrier disruption indicate an improvement in skin barrier function, such that less water is lost through the skin barrier.

TEWL measurements will be taken from the randomized designated treatment sites for the test product sites and the control (untreated) site at each measurement interval.

Bioinstrumental Method to Measure Firmness and Elasticity of Human Skin⁶⁻⁸

The biomechanical properties of human skin are a complex combination of elastic (elastin fibers) and viscous (collagen fibers and surrounding intercellular ground substance) components. The

Cutometer allows the measurement of the viscoelastic properties of the skin in vivo. The measuring principle of the Cutometer is based on suction. A defined negative air pressure is created and applied on the skin surface through the opening of a probe drawing the skin into its aperture. The resulting vertical deformation of the skin is measured by determining the depth of skin penetration into the probe. This is achieved by a noncontact optical system consisting of a light transmitter and a light recipient. Two glass prisms project the light from transmitter to recipient, where the diminution of the infrared light beam depending on the penetration depth of the skin is measured.

Cutometer MPA 580 (Courage and Khazaka, Germany) will be used to measure skin firmness and elasticity.

Clinical Photography for Expert Grading Analyses of Fine Lines and Wrinkles (Eye Area) and Skin Lifting (Eye Area)⁹⁻¹¹

Photographs are taken in accordance with regulations provided by consumer protection agencies such as the Federal Trade Commission, the Food and Drug Administration and several other regulatory authorities. The following guidelines are followed for the before and after images: 1) Head and body position is the same, 2) same lighting conditions are used, 3) the distance from the camera to the participant remains consistent, 4) same room and background, 5) no makeup and/or jewelry, 6) hair styling (lifted away from face/neck and use of hair gel) remains consistent, 8) facial expressions remain consistent, and 7) clothing color (if visible in photograph) remains consistent. Images are not altered by the testing facility.

Clinical photographs of subjects' faces (frontal, left lateral and right lateral) will be taken and evaluated with Canfield VISIA CR system using the Standard 1 modality.

Photographs obtained of the face will be evaluated for the following parameter. Each subject will have the test site evaluated based on the following scales: *(Half point increments will be used)*.

Parameter	Scale
Skin Lifting eye area	7-9 = Severe appearance of sagging skin 4-6 = Moderate appearance of sagging skin 1-3 = Mild appearance of sagging skin 0= No appearance of sagging skin
Fine Lines and Wrinkles eye area	7-9 = Severe appearance of fine lines and wrinkles 4-6 = Moderate appearance of fine lines and wrinkles 1-3 = Mild appearance of fine lines and wrinkles 0= No appearance of fine lines and wrinkles


Self-Assessment Questionnaire

Each subject will be instructed to complete a self-assessment questionnaire provided by the Sponsor at the immediate (15 minute), 24 hour, week 4, week 8, and week 12 post-treatment intervals.

VIII. PROCEDURE

1. Subjects will report to the facility a minimum of five (5) days prior to study start.
2. Prior to beginning any study related activities, subjects will be given an informed consent form, photography release form, HIPAA form, and code of conduct form to read.
3. Once subject has completed reading they will be interviewed, in private, by ALS to ensure their understanding of the aforementioned forms and be given the opportunity to ask any study related questions.
4. Subjects who agree to sign the aforementioned forms will be asked to complete a medical history form. Subjects declining to sign any of the forms will be dismissed from the study.
5. Subjects will be enrolled on the basis of the subject selection criteria. Subjects failing to meet criteria will be dismissed from the study.
6. Enrolled subjects will be given specific instructions prohibiting use of all personal care products (i.e. lotions, creams, serums, cleansers) on the test sites (face and volar forearms) for the entire study duration, including washout period (5-days for face; 3-days for forearms).
7. Subjects will be instructed to continue use of all cosmetics (e.g. foundation, blush, eye makeup) as long as they do not contain anti-aging ingredients. Cosmetics will be inspected and approved by ALS staff to confirm it does not contain anti-aging ingredients.
8. Enrolled subjects will begin the washout period using only the provided neutral soap, sponsor supplied sunscreen and approved cosmetics.
9. Following the 5-day (3-day for forearm) washout period, subjects will return to the testing facility. Subjects will be instructed to wear clothing that does not cover their forearms on the evaluation day.
10. Subjects will be instructed to cleanse their face with a neutral cleanser and pat dry. The volar surface of the forearms will be gently wiped with a damp disposable washcloth and patted dry with a paper towel by trained BCS staff.
11. Trained ALS staff will mark two (2) test sites on the volar surfaces of the forearm (1 site on each arm). Each test site will be 4cm X 4cm. Test sites will be placed at least 2cm from the wrist joint and at least 2cm from elbow joint. The control site and treatment sites, will be randomly assigned using a computer generated randomization code. See Figure 1 schematic representation of test sites.

Figure 1: Schematic representation of test sites*



* Product application will be randomly assigned within the test sites.

12. Measurements will be made within these test sites throughout the study period. The TEWL probe will be cleaned between site measurements with a Kim Wipe®.
13. Thereafter, subjects will equilibrate by remaining quietly seated for a minimum of thirty (30) minutes in a room maintained at approximately 20-24°C and 30%-50% relative humidity. Temperature and humidity will be recorded during subject testing.
14. Following equilibration, subjects will have the below procedures/ measurements performed by trained ALS staff:

Baseline (pre-treatment)

- a. Clinical photography: VISIA-CR (frontal, left lateral, right lateral)
- b. Skin hydration measurements on site 1 and 2
- c. Skin elasticity and firmness measurement on site 1 and 2
- d. Skin barrier function measurement on site A and B

See schematic representation of test sites, Figure 1 and 2.

15. Following baseline measurements, subjects will be instructed to apply test product to their face per sponsor provided use instruction. ALS staff will supervise application to ensure proper application.
16. Following baseline measurements, test product application on the designated treatment test sites will be performed by trained BCS staff.

Test Product Application Instructions

Approximately 2 mg/cm² of product will be applied to its designated treatment site on each subject, determined by computer generated randomization code, with a finger cot and gently rubbed into the skin until absorbed.

Site A: Test Product – TEWL Maintenance

Site B: Untreated Control – TEWL Maintenance

17. Following application, subjects will remain in exam room.

18. At 15 minutes (± 5 minutes), subjects will have the below procedures/measurements performed by trained ALS staff:

15 minute (± 5 minutes) post-treatment

- a. Skin hydration measurements on site 1 and 2
- b. Skin elasticity and firmness measurement on site 1 and 2
- c. Skin barrier function measurement on site A and B
- d. Self-assessment questionnaire

19. Following immediate measurements, subjects will be dismissed from the testing facility and will be instructed to return approximately 23 hours and 30 minutes (± 30 minutes) post-application. Subjects will be instructed not to wet (i.e., no showering, bathing or swimming) or apply products to their volar forearms until after the 24-hour measurements.

20. Subjects will be given the test product with product use instructions as directed by the Sponsor to use on the face for the duration of the study. Subjects will continue usage of the supplied cleanser and SPF distributed at washout for the entire study duration.

21. At 23 hours and 30 minutes post-treatment (± 30 minutes), subjects will equilibrate by remaining quietly seated for a minimum of thirty (30) minutes in a room maintained at approximately 20-24°C and 30%-50% relative humidity. Temperature and humidity will be recorded during subject testing

22. Following equilibration, subjects will have the below procedures/ measurements performed by trained ALS staff:

24 hour (± 1 hour) post-treatment

- a. Skin barrier function measurements on site A and B
- b. Self-assessment questionnaire

23. Subjects will be informed to return 4 weeks (± 3 days), 8 weeks (± 3 days) and 12 weeks (± 3 days). Test product will be weighed for compliance. Subjects suspected of non-compliance will be dismissed from study participation. Subjects will be instructed not to use test product on the day of their scheduled visit.

24. Subjects will be instructed to cleanse their face with a neutral cleanser and pat dry.

25. Thereafter, subjects will equilibrate by remaining quietly seated for a minimum of thirty (30) minutes in a room maintained at approximately 20-24°C and 30%-50% relative humidity. Temperature and humidity will be recorded during subject testing.

26. Following equilibration, subjects will have the below procedures/ measurements performed by trained ALS staff:


Week 4 (± 3 days), Week 8 (± 3 days) and Week 12 (± 3 days) post-treatment

- a. Clinical photography: VISIA-CR (frontal, left lateral, right lateral)
- b. Skin hydration measurements on site 1 and 2
- c. Skin elasticity and firmness measurement on site 1 and 2

d. Self-assessment questionnaire

27. Subjects will return the remaining test product at week 12 and will be dismissed from the study.

Figure 2: Schematic representation of test sites



Outline of Procedures:

Claim	Methodology	Intervals					
		Baseline	15 Minutes	24 Hours	4 Weeks	8 Weeks	12 Weeks (Final)
Improves skin hydration / moisturization	Corneometer	Yes	Yes	N/A	Yes	Yes	Yes
Improves skin barrier function	TEWL	Yes	Yes	Yes	N/A	N/A	N/A
Improves skin firmness and elasticity	Cutometer	Yes	Yes	N/A	Yes	Yes	Yes
Reduce appearance of fine lines and wrinkles in the eye area	Expert Grading of photos obtained by VISIA CR	Yes	N/A	N/A	Yes	Yes	Yes
Skin Lifting in the eye area	Expert Grading of photos obtained by VISIA CR	Yes	N/A	N/A	Yes	Yes	Yes
Subjective	Questionnaire*	Yes	Yes	Yes	Yes	Yes	Yes

*Questionnaire is limited to 25 questions per interval.

IX. ADVERSE EVENTS

An adverse event is any untoward medical occurrence, whether or not it is considered study related, including death, experienced by a subject. An event may consist of a disease, an exacerbation of a pre-existing illness or condition, an occurrence of an intermittent illness or condition, a set of related symptoms or signs, or a single symptom or sign.

A serious adverse event (SAE) as defined in the CFR 312.32 is “any experience that is fatal or life threatening, is permanently disabling, requires inpatient hospitalization, or is a congenital

anomaly, cancer, or overdose”. All serious adverse events will be reported to the sponsor within 24 hours of ALS notification.

Each adverse event must be promptly recorded and sufficiently documented by the Study Director in the source documentation and case report form even if the adverse event is assessed by the Study Director as unlikely to be related to the study. Adverse events are graded on a scale of severity (mild, moderate, severe, or life threatening) and on a scale of relationship to the product (unknown, unrelated, unlikely, possible, probable, or definite). All adverse events will be reported to the Sponsor within five business days. All adverse events will be followed up until resolved, stabilized, the subject is lost to follow-up or the event is otherwise explained. All follow-up information should be reported to the Sponsor.

If, according to the Investigator, medical care is warranted, appropriate referrals will be made. ALS will follow all adverse events until resolution.

The contact information to report SAE is:

Rania Ibrahim, Ph.D.
rania.ibrahim@alsglobal.com
Work: (602) 227-1154
Cell: (602) 689-2829

X. RISKS / DISCOMFORTS

As with the introduction of any new personal care product, burning, stinging, itching, redness or irritation may occur at the test sites. There also may be risks and discomforts, which are not yet known.

XI. SUBJECT DISCONTINUATION

Criteria for the discontinuation of a subject during the study will include the following:

1. Significant protocol violation
2. Serious adverse experience
3. Request of the subject
4. Any unmanageable factor, in the Investigator’s opinion, that may significantly interfere with the protocol or interpretation of results.

XII. PROTOCOL AMENDMENT

Any changes to the study protocol will be approved in writing by the client and ALS prior to implementation in the study.

XIII. DATA ANALYSES

Statistical analyses will test the hypothesis that the pre-treatment values of each parameter are statistically different from its post-treatment values. Statistical significance will be declared if the two-tailed p -value is ≤ 0.05 .

Subject scores for each parameter in questionnaires will be presented in a tabular format. The number and percentage of subjects responding in favor of the test product will be reported. Statistical analysis will be performed using a z -test. Statistical significance will be declared if the p -value is ≤ 0.05 .

XIV. STUDY REPORT

Topline reports (Week 4, Week 8, and Week 12) will be issued to the sponsor within 5 business days of interval completion.

Final report will be issued to the sponsor within four weeks of study completion.

XV. DATA ARCHIVES

All original samples, raw data sheets, technician's notebooks, correspondence files, a copy of final report and remaining specimens will be maintained on the premises of the clinic in limited access marked storage files. A duplicate copy of the final report will be separately archived at ALS Pharmaceutical, Beauty and Personal Care Laboratories, Torrance, CA.

REFERENCES

1. Information and operating instructions for the Cutometer MPA 580 and its probes.
2. Jemac GB, Serup J. Epidermal Hydration and Skin Mechanics. *Arch Derm- Venereol.*: 70: 245-250 (1990).
3. Information and instruction manual for the DermaLab Series SkinLab Combo.
4. Leveque JL, Garson JC, de Rigal J. Transepidermal Water Loss from Dry and Normal Skin. *J Soc Cosmet Chem* 1979, 30: 333-343.
5. Elsner P, Berardesca E, Wilhelm KP, Maibach, HI. In *Bioengineering of the Skin*, Skin Biomechanics 2001. CRC Press, 117.
6. Undine B, Elsner P. Hardware and Measuring Principle: The Cutometer. In the *Bioengineering of the Skin – Skin Biomechanics*. 2002; Pp 91-98
7. Agache P, Varchon D. Skin Mechanical Function. In the *Measuring the Skin*. 2004; Pp 429-467
8. Information and operating instructions for the Cutometer MPA 580 and its probes.
9. *Arch. Dermatol.*, 128: 347-351, 1992.
10. *Br. J. Dermatol.*, 130: 167-173, 1994.
11. *Skin Pharmacol. Appl. Skin Physiol.*, 16: 100-107, 2003

APPENDIX B RAW DATA

A) Skin Hydration - Corneometer

ID	Baseline						15 Minute						Week 4						Week 8					
	Right PA			Left PA			Right PA			Left PA			Right PA			Left PA			Right PA			Left PA		
	Rep 1	Rep 2	Rep 3	Rep 1	Rep 1	Rep 1	Rep 1	Rep 1	Rep 1	Rep 2	Rep 3		Rep 1	Rep 2	Rep 3	Rep 1	Rep 2	Rep 3	Rep 1	Rep 2	Rep 3	Rep 1	Rep 2	Rep 3
18	28.8	25.6	25.3	33	28.3	28.8	72.1	73.3	70.2	71.1	73.6	73	64.6	62.9	61.2	62.3	61.7	60.3	68.9	69.3	67.3	52.2	47.9	53
841	27.2	27.7	27	27.9	28.6	29.4	60.2	62.4	62.3	59.3	57.1	57.7	40.1	39.1	40.6	36.3	37	36	50.8	52	51.1	50.2	51.4	53.5
871	41.4	41.7	40.4	38.8	37.5	38.7	52.9	50.7	51.9	54.2	53.1	53.9	50	48.5	47.8	57.1	56.5	54	54.4	58.4	57.4	45.9	46.3	43
1440	45.6	45.2	44.1	41.6	42.9	45	56.7	55.3	53.4	54.8	54.7	55.4	61.2	59	59	54.5	57.5	56.6	64.1	63.7	64.1	66.3	66.2	67
1566	40.6	41.1	40.6	43.5	46.4	44.8	56	57.2	57.3	65.1	67.8	65.6	49.7	52.3	51	48.5	49.5	48.9	49.6	49.6	48.5	49.5	49.9	49.1
2337	35.3	38.8	34	38.8	39.7	39.6	65.6	62	66.7	64.2	61	62.7	71.3	70.4	67.9	63.5	63.5	66.8	53.4	56.1	54.7	48.7	45.7	46.9
3441	40	40.9	39.7	37.8	38.7	38	61.2	59.4	61.5	58.9	60.4	62.2	49.5	45	46	48.5	50.1	49.1	54.3	57.7	57.2	48.6	50.6	49.9
3445	22.4	24.6	22.9	25.9	29.5	27.8	41.2	44.1	43.8	42	45.2	41.6	50.9	48.2	48.3	46.9	45.7	41.1	44.1	42.9	44.4	42.2	44.8	43
3894	44.1	42.4	42.2	49.5	47.2	51.2	56.2	56.5	58	56.6	58.7	58.2	52.1	51.5	53	53.1	54.5	53	53.6	54	57.1	56.8	55.6	56.6
4321	39.9	40.5	43.7	41.3	45.7	43.5	67.7	65.1	65.3	63.1	67.9	65.1	64.4	63.9	63.7	65.5	65.8	65.3	63.3	64	66.7	57.9	59.2	59.3
4988	32.2	33.7	32.4	30.7	29.7	28.8	52.3	53.8	55.2	46.3	45.9	46.8	38.8	37.7	39.4	36.6	39.3	37.9	39.7	38.5	37	35.5	35.3	36.1
5107	45	46.3	45.7	34.7	35.1	35.1	57.4	57.4	53.7	41.2	41.3	39.3	67.9	66.5	67.7	59.5	58.9	61.7	59.1	60.7	57.7	52.9	50.9	52.5
6217	18.7	20.3	19.1	20.4	22.3	19.8	53.1	54.2	51.9	41.4	40.6	42.5	41.9	37.4	37.7	34.7	34.6	34.7	46.6	46.4	44.4	44.2	45.9	44
6987	42.2	42.6	42.9	42.7	44.3	39.9	59.1	59.9	61.6	65	65.7	68.7	50.5	54.8	49.7	56.2	54.5	54.4	53	52.1	53.5	44.4	43.7	45.3
7102	45.7	45	43.8	50.1	46.3	51	74.8	75.7	73.7	69.2	69	73.4	68	64.4	67.7	70.3	72.8	73.3	69.1	69.7	69	60.1	61.6	60.7
7226	61.5	62.1	62.7	55	57.4	57.8	69.9	66	68.2	62.1	61.2	61.8	61.4	62.8	63.9	62.4	58.1	59.4	77.4	77.1	76	71.2	70.8	71.1
7767	44.8	45.7	44	43	43.1	44.3	53.8	53.4	53	51.5	51.1	52.7	62.8	66.3	67	61.7	59.7	61.8	57.5	60.2	58.2	59	60.7	58.5
14404	39	38	42.4	42.4	41.6	42.8	60.5	60	64	61.6	56.8	57.1	56.4	59.9	56.2	56.8	57.7	56.3	59	56.6	56.5	56.7	58.2	56.7
14578	33.2	34.9	37.1	21.7	23.7	24.1	65.3	65.4	62.3	52	52.1	50.1	53.7	52.2	50.1	54.8	52.3	53.6	54.7	52.6	51.2	33.1	33.2	34.3
15152	32.7	31.5	30.3	38.6	35.3	35.6	70.1	73.5	70	71.5	73.2	72.6	68	65.5	68	62.9	64	62.8	77.1	78.7	78.9	75.6	78.5	77
18766	39.1	39.1	37.7	35	39.5	37.3	59.5	56.9	58.2	60.9	58.1	58.2	69.3	67.1	68	47	45.6	50	66.6	62.4	65.8	62.1	64.5	62.3
18949	45.6	48.2	49.5	51	51.6	51.7	68.7	66.3	66.9	72.2	73.9	69.9	58.8	59.7	61.1	62	60.4	62	59.8	63.9	64.1	64.6	63.2	61.5
19606	32.6	32	31.7	31.8	30.6	29.1	48.9	48.9	49.5	43.6	42.2	44.8	52.6	51.4	51.7	49.4	48.4	50.8	51.9	54.1	52.2	54.3	50.6	54.3
19674	32.2	30.6	30.7	26.2	29.8	28.4	77.8	77	77.3	72.4	71.1	74.3	41.6	42.1	42.1	34.6	37.4	37.3	58.7	61	58.9	48.5	48.7	48.6
19735	27.5	29.6	27.9	42.6	40.2	40.9	69.8	73	73.5	61.9	64.5	62.7	59.9	62.6	62.7	60.1	59.7	57.9	59.5	57.2	59.1	54.9	55.4	54.7
22705	33.6	34.7	32.8	31	32.8	34	61.7	59.5	61.5	66.2	70.6	65.8	47.9	43.8	45.9	49.4	49.2	49.7	49.1	47.5	52.2	48.4	47.4	48.1
23348	21.7	21.3	21.5	29.3	33.2	32.9	40.6	43.4	41.9	41.8	42.7	40.1	61.3	58.5	59.7	47.3	51.3	48.4	47.5	48.4	46.9	45.4	48.3	47.7
23680	23.1	25.2	23.8	36.7	35.1	35.9	62.5	63.7	62.6	64.2	63.6	62.8	52.9	53.3	53.9	53.2	52.6	54.5	54.4	53.5	53.9	60.1	60.4	57.6
23758	42.9	42.1	42.5	43.3	41.2	43.2	70.1	71.1	69.2	63.7	61.6	62.3	45.6	41.8	44.5	44.2	41.6	45.4	59.5	60.1	59.7	58.7	55.6	57.6
23961	27.2	27.6	29.1	15.8	19.3	19	69	70.5	70.7	62.2	59.9	58.7	74.8	76.3	75.5	60.4	59.6	62	43	47.3	44	37.2	36.8	34.8

25078	28	31.3	30	34.6	33.4	35.2	54	56.9	57.1	51.4	51.6	52.5	46.9	43.4	45.6	43.9	43.4	43	41.9	42.9	44.2	40.7	43	42.8
26648	59.9	56.5	55.8	56.1	59.3	55.2	65.8	69	68.7	67.1	67.5	67.9	70.4	69.8	69	57.5	58.2	57.4	62.3	65.1	61.4	62.7	62.3	63.6
27773	18.5	19.2	17.5	24.8	25.4	23.5	60	58.5	57.2	63.4	61.3	60.4	50.9	52	53.6	44.9	46.7	48.5	30.6	34.5	33.6	38.5	38	40.5
27957	32.5	33	34.3	34	36.5	32.9	71.9	70.8	73.9	69.2	65.3	67.8	61.1	58.9	60.8	62.8	65.2	63.2	46.2	42.4	42.6	54.2	53.9	55.6
28936	48	49.7	47.5	44.7	45	43	68	70.3	67.4	64	68.1	65.5	65.9	63.8	63.5	60.6	60.7	58.1	65.1	63.3	62.7	64.1	67.7	66.3
28966	26.4	26.6	27	26.5	29.5	25	59.7	55.7	56.9	57.2	56.8	61	51	54.8	53.8	50.1	50.1	48.1	49.8	49	46.9	48.2	45.8	48.5
31089	17.5	19.3	14.6	17.1	17.1	20.5	64.6	67.3	67.5	63.1	62.7	64	47.5	49.4	45.6	49.8	50.4	52.8	47.5	48.9	48.2	46.7	47	46.5
33822	50.4	47.5	50.1	49	47.8	50.1	66.6	65.4	64.1	62.3	62.6	66.4	53.8	55.4	55.2	55.2	56.4	57.8	54	55.2	54.1	55.4	52.8	52.8
33882	35.2	35.4	30.6	31.5	28.8	33.8	68.6	65.2	66.4	68.8	71.6	73.2	66.7	67.3	65.4	59.7	58.3	59	53.4	57.4	57	57.2	57.8	57.1
33907	31.8	33.4	33.3	35.1	34.9	36.7	57.2	56.4	59	58.3	57.4	59.3	54.7	54.4	57.3	60.2	61.6	58.5	56.5	56.2	56.9	48.8	48.4	51.9
33984	30.7	27.8	29.7	37.4	38.1	42.1	64.5	62.9	66.7	64.8	66.5	67.8	50.5	49.7	51.5	52.5	51	51.4	45.4	46.5	45.9	49.5	48.9	53.6
35485	34.8	32.2	34.9	46.1	49.5	48	63.9	68.1	63.8	66.1	63.9	63.2	63.5	64.4	34.9	62	59.9	64.2	67.6	66.4	65.4	67.6	71.2	69.9
35490	36.9	41.1	36.4	41.6	39.4	40.1	70.5	71.3	67.7	68.1	69	65.9	55.1	52.9	52.2	51.1	52.2	52.3	52.3	55.1	52.6	55.7	54.2	54.9
35497	26.2	30	26.2	43.7	42.5	42.8	72	73.2	74.8	86.4	89.7	86	71.5	72.8	70.7	72.4	74.3	73.6	74	78	75.4	79	75.7	76
37445	30.5	29.4	28.5	36.4	35.7	38.4	65.3	68.2	64.3	61.9	61	60.4	51	48.8	48.8	45.2	45.7	43.6	49.6	49.9	51.3	46.5	45.9	44.9
40044	38.7	38.9	38.4	32.4	31.7	31.3	69.1	70.5	69.4	65.1	68.3	65.2	43.1	45.3	47.2	40.7	39.3	39.8	49.3	49.6	49.4	39.9	38.1	38.2
40236	38.6	38.3	38.6	39.5	40.9	39.7	58.7	60.2	63.5	53.8	54.4	55.3	65	61.6	62.2	56.6	58.6	55.9	64.1	60.2	64	59.4	61.5	59.6
40355	50.4	50.9	52.5	50.2	52.2	50.7	63.7	59.3	59	67.9	67.9	64.6	53.9	51.2	52.7	52	56.1	52.6	53	51.3	49.2	55.9	57.5	58.6
40637	30.8	30.9	26	26.1	24.9	27	57.4	56.5	58.7	61.7	61.1	61.2	44.8	44.4	46.2	43.5	44.2	47.2	61	60.6	61.8	58.8	57.8	59
40809	35.7	34.8	33	32.9	35.6	30.6	52.7	52.4	54.9	54	51.1	54.4	58.1	55.8	53.1	49.4	48.7	44.9	94.2	96.4	92.7	70.7	69.9	73.3
41118	18.1	18.6	17.9	23.3	22.5	22	69.2	68.2	70.7	65.8	65.5	68.8	54.1	53.1	55.3	47.3	49.4	47.9	58	58	57.7	49.9	49.3	50.9
42601	42.1	43.5	42.4	38.3	38.8	38.4	60.1	60.3	57.3	56	53	52.6	50.8	51.8	51.8	47.5	50.4	49.9	51.3	52.5	51	49.5	48.5	51.1
Average	36.22						61.56						54.46						55.07					
SD	9.16						8.12						8.51						9.87					

B) Skin Firmness (R0) - Cutometer

ID	Baseline		15 Minute		Week 4		Week 8	
	Right PA	Left PA	Right PA	Right PA	Right PA	Left PA	Right PA	Left PA
18	0.4830	0.4010	0.3630	0.4170	0.4780	0.4420	0.3170	0.3800
841	0.3380	0.3630	0.2640	0.2250	0.3180	0.3710	0.3160	0.3790
871	0.1450	0.1780	0.1930	0.2890	0.2140	0.1780	0.2650	0.2820
1440	0.3990	0.4120	0.4150	0.3380	0.2870	0.3130	0.2250	0.3720
1566	0.3270	0.3140	0.2540	0.3150	0.3900	0.2630	0.3990	0.3000
2337	0.4610	0.2890	0.3740	0.2500	0.3450	0.3380	0.3070	0.3000
3441	0.3810	0.3530	0.3680	0.3130	0.3310	0.2160	0.3380	0.4050
3445	0.2560	0.3320	0.3400	0.3090	0.3070	0.3050	0.3670	0.3230
3894	0.3370	0.2620	0.2560	0.2510	0.2190	0.1930	0.2620	0.1830
4321	0.3270	0.3150	0.3220	0.2980	0.2770	0.3910	0.2520	0.2520
4988	0.2630	0.2390	0.2260	0.2810	0.1940	0.2080	0.2460	0.1870
5107	0.3470	0.3390	0.3160	0.3340	0.2820	0.3570	0.2550	0.2470
6217	0.2570	0.2660	0.1960	0.1840	0.1820	0.1670	0.2750	0.2750
6987	0.2500	0.2360	0.2220	0.2740	0.1790	0.1690	0.1900	0.1940
7102	0.2620	0.3160	0.2910	0.3150	0.2620	0.3060	0.3280	0.1520
7226	0.2850	0.3370	0.2700	0.3490	0.2890	0.3940	0.2740	0.3790
7767	0.3570	0.3500	0.2960	0.3600	0.3020	0.3960	0.2780	0.2750
14404	0.3210	0.3420	0.1870	0.3010	0.2600	0.2720	0.3380	0.2550
14578	0.1500	0.2100	0.2560	0.1910	0.2320	0.2380	0.2830	0.2400
15152	0.4160	0.4860	0.3350	0.5030	0.2600	0.3470	0.3450	0.3860
18766	0.2690	0.3540	0.2540	0.3380	0.3230	0.3510	0.3490	0.3360
18949	0.3940	0.4500	0.3680	0.4020	0.3850	0.3680	0.3570	0.3770
19606	0.2420	0.2330	0.2750	0.2410	0.2470	0.2250	0.2790	0.1830
19674	0.1660	0.2400	0.1890	0.2210	0.2590	0.2250	0.2170	0.2510
19735	0.3240	0.3860	0.3080	0.3420	0.3210	0.3500	0.3500	0.4320
22705	0.2620	0.2900	0.2640	0.2760	0.2470	0.3090	0.2880	0.2530
23348	0.2890	0.3350	0.2930	0.3280	0.3230	0.3020	0.2220	0.3160
23680	0.3680	0.4040	0.3040	0.3760	0.3080	0.3170	0.3120	0.2480
23758	0.3730	0.2940	0.3410	0.2780	0.4070	0.3330	0.3910	0.3080
23961	0.3180	0.3510	0.3540	0.3630	0.3040	0.2570	0.4180	0.3460
25078	0.3370	0.2730	0.2740	0.3320	0.2790	0.3860	0.3770	0.3100

26648	0.4330	0.5230	0.4590	0.5540	0.5810	0.3750	0.3620	0.4690
27773	0.2920	0.3220	0.2940	0.3060	0.3670	0.3650	0.2210	0.3310
27957	0.3420	0.3520	0.3490	0.4000	0.4270	0.3040	0.3460	0.3390
28936	0.2550	0.3000	0.2660	0.3040	0.2220	0.2780	0.2680	0.2690
28966	0.3880	0.3470	0.3860	0.2530	0.3860	0.3620	0.3610	0.4505
31089	0.2200	0.1930	0.2900	0.2100	0.2830	0.2370	0.2760	0.2620
33822	0.4140	0.3820	0.6540	0.4460	0.5080	0.3880	0.3670	0.2890
33882	0.3500	0.2520	0.2760	0.2470	0.1980	0.2540	0.2930	0.1860
33907	0.2740	0.3350	0.2310	0.2600	0.1860	0.2260	0.1530	0.1990
33984	0.2680	0.3510	0.3620	0.4430	0.4320	0.4310	0.3470	0.3460
35485	0.2730	0.3560	0.2500	0.3340	0.2350	0.2330	0.3120	0.2860
35490	0.3270	0.4740	0.4100	0.4040	0.3600	0.3710	0.3650	0.3270
35497	0.2550	0.3470	0.2280	0.3810	0.3350	0.3860	0.3580	0.3480
37445	0.2710	0.3470	0.2500	0.2840	0.2920	0.2110	0.2540	0.2730
40044	0.3170	0.3900	0.3140	0.3340	0.3120	0.3880	0.3440	0.4230
40236	0.2860	0.3560	0.2790	0.3130	0.2790	0.2500	0.2370	0.2690
40355	0.3220	0.2700	0.3090	0.2180	0.1870	0.1860	0.2940	0.2220
40637	0.3300	0.3530	0.3470	0.3390	0.3160	0.3510	0.3890	0.2990
40809	0.3570	0.4010	0.3040	0.3410	0.3720	0.3960	0.3700	0.4360
41118	0.1940	0.3040	0.2700	0.2510	0.2700	0.3510	0.2740	0.2630
42601	0.2730	0.2840	0.2110	0.2440	0.2320	0.2040	0.2660	0.2360
Average	0.3205		0.3093		0.3041		0.3031	
SD	0.0651		0.0686		0.0734		0.0587	

C) Skin Elasticity (R2) - Cutometer

ID	Baseline		15 Minute		Week 4		Week 8	
	Right PA	Left PA	Right PA	Left PA	Right PA	Left PA	Right PA	Left PA
18	0.6770	0.6334	0.5840	0.7242	0.4623	0.5339	0.6688	0.5895
841	0.5769	0.5592	0.5303	0.4622	0.5818	0.4178	0.4019	0.3562
871	0.4690	0.6461	0.5440	0.7439	0.5701	0.6180	0.4453	0.5532
1440	0.4812	0.4272	0.4651	0.5828	0.4634	0.4058	0.4533	0.5269
1566	0.5352	0.4809	0.5157	0.4698	0.5282	0.4259	0.4586	0.4200
2337	0.4577	0.5052	0.3957	0.5560	0.3565	0.2899	0.2541	0.5433
3441	0.4147	0.5722	0.6114	0.5879	0.3988	0.6204	0.4201	0.4074
3445	0.5508	0.5964	0.6059	0.5307	0.3844	0.2852	0.4087	0.8142
3894	0.4570	0.5725	0.4375	0.6574	0.5799	0.5078	0.4046	0.4426
4321	0.4495	0.4540	0.4876	0.5134	0.6173	0.6650	0.3929	0.3968
4988	0.6692	0.6904	0.6239	0.5552	0.7113	0.5433	0.6667	0.4813
5107	0.4697	0.4897	0.4652	0.4910	0.6383	0.6134	0.5451	0.5263
6217	0.7082	0.6880	0.6327	0.8261	0.3846	0.4910	0.5055	0.6691
6987	0.7240	0.6737	0.6171	0.5584	0.6480	0.4734	0.4368	0.5567
7102	0.5763	0.6741	0.6564	0.7587	0.6031	0.5327	0.6860	0.7039
7226	0.4386	0.4154	0.4593	0.3954	0.4429	0.3706	0.3905	0.4512
7767	0.4090	0.3971	0.4392	0.5722	0.4205	0.5253	0.5036	0.5382
14404	0.5826	0.4620	0.5455	0.5316	0.5115	0.5110	0.6095	0.6196
14578	0.6600	0.6190	0.6758	0.6178	0.6293	0.7101	0.4382	0.6292
15152	0.5337	0.5556	0.7224	0.7078	0.3769	0.4899	0.5130	0.4663
18766	0.6134	0.6864	0.6378	0.6213	0.5697	0.4872	0.5587	0.7262
18949	0.3629	0.4378	0.3451	0.4751	0.3325	0.3587	0.3838	0.3263
19606	0.4256	0.5536	0.5455	0.4938	0.2672	0.4267	0.5484	0.5137
19674	0.4759	0.5542	0.5873	0.5339	0.5946	0.5111	0.7143	0.6414
19735	0.6667	0.6088	0.7922	0.5906	0.5452	0.4371	0.5229	0.4769
22705	0.7176	0.5690	0.7917	0.6304	0.5911	0.5469	0.5104	0.7312
23348	0.3806	0.4806	0.5119	0.6220	0.5449	0.5927	0.4640	0.3797
23680	0.4239	0.4084	0.3487	0.4840	0.2987	0.3533	0.4455	0.2823
23758	0.5576	0.5306	0.4428	0.5683	0.3096	0.3483	0.4578	0.4318
23961	0.5818	0.6496	0.6751	0.6832	0.5296	0.5175	0.3493	0.4393
25078	0.3680	0.5348	0.6022	0.5994	0.4803	0.4715	0.3820	0.6000

26648	0.4342	0.4914	0.6275	0.5686	0.7831	0.6427	0.5166	0.4414
27773	0.4144	0.5714	0.5578	0.5425	0.3297	0.5370	0.3348	0.5347
27957	0.4474	0.4432	0.4212	0.5000	0.6300	0.3618	0.6329	0.3658
28936	0.7020	0.6033	0.8195	0.5428	0.6351	0.5468	0.5709	0.5167
28966	0.5232	0.4524	0.5544	0.5455	0.4689	0.3425	0.3573	0.3746
31089	0.5500	0.5959	0.5828	0.6143	0.4700	0.6414	0.5507	0.6069
33822	0.2971	0.5105	0.3165	0.3049	0.2067	0.3840	0.2807	0.3668
33882	0.4200	0.5754	0.6159	0.6559	0.5707	0.5866	0.4027	0.4516
33907	0.5438	0.6328	0.6580	0.6231	0.5806	0.6327	0.7974	0.5477
33984	0.4739	0.4387	0.5221	0.4989	0.5463	0.4014	0.4179	0.4017
35485	0.7985	0.7051	0.7360	0.7156	0.5617	0.5794	0.5641	0.5664
35490	0.7676	0.6772	0.6878	0.6510	0.5361	0.5822	0.4466	0.4832
35497	0.7098	0.6859	0.6404	0.7165	0.7463	0.7953	0.6508	0.6379
37445	0.6421	0.6628	0.6040	0.6585	0.6541	0.6114	0.5000	0.6300
40044	0.5237	0.5385	0.4745	0.4251	0.4038	0.4871	0.4767	0.4255
40236	0.4720	0.6854	0.3943	0.5783	0.4588	0.5960	0.5696	0.3494
40355	0.4348	0.5037	0.4628	0.5459	0.5348	0.5914	0.3980	0.5045
40637	0.5455	0.5382	0.5562	0.5280	0.4430	0.4359	0.4961	0.4147
40809	0.5798	0.3242	0.5921	0.4487	0.4892	0.3384	0.2946	0.4014
41118	0.4691	0.6480	0.4889	0.4900	0.4704	0.6068	0.4307	0.4981
42601	0.6154	0.6303	0.6635	0.6025	0.5517	0.5588	0.3722	0.4153
Average	0.5463		0.5690		0.5075		0.4921	
SD	0.0944		0.0939		0.1041		0.0949	

D) Skin Barrier Function- TEWL (n=50)

ID	Untreated (Control)			Treated		
	Baseline	15 Minute	24 Hour	Baseline	15 Minute	24 Hour
18	4.1	3.8	4.2	2.9	1.4	1.9
841	2.8	3.2	2.6	2.2	1.5	1.8
871	2.9	2.6	3.1	3.0	1.1	2.2
1440	3.1	3.8	2.4	3.1	1.0	1.4
1566	3.3	2.4	2.5	3.0	2.0	1.6
2337	2.5	2.9	3.0	2.5	1.8	2.4
3441	4.0	3.2	3.3	3.0	2.0	2.5
3445	2.0	2.1	2.5	2.1	1.4	1.8
3894	2.6	3.3	3.0	3.4	2.2	2.4
4321	4.0	4.5	4.3	4.5	1.6	2.4
4988	5.4	5.2	5.7	5.0	3.7	3.8
5107	3.2	3.8	4.1	3.2	1.8	2.6
6217	2.2	2.3	2.5	2.5	2.0	1.6
6987	2.5	2.1	2.6	3.2	1.4	2.2
7102	2.2	2.5	2.9	2.5	1.6	1.8
7226	3.5	3.2	4.1	4.0	3.2	2.6
7767	3.4	3.0	4.3	3.0	1.7	2.8
14404	3.1	3.0	3.6	3.6	2.4	2.4
14578	4.5	3.7	5.4	3.9	2.4	3.4
15152	3.9	4.4	3.6	3.9	2.9	2.5
18766	6.5	6.5	7.3	6.6	2.5	5.3
18949	2.7	2.6	3.1	2.3	1.8	1.9
19606	6.2	6.2	6.8	7.6	5.3	5.2
19674	2.2	1.3	1.8	1.7	0.7	1.0
22705	2.3	1.8	2.4	2.2	1.5	1.3
23348	4.5	3.7	4.1	2.4	2.0	2.3
23680	5.2	5.4	5.7	3.8	1.7	2.1
23758	3.7	4.5	3.8	3.9	2.2	2.4

23961	3.7	3.3	4.0	3.5	1.8	3.0
25078	1.7	2.6	2.1	2.5	1.2	1.7
26648	2.2	2.9	2.2	2.4	1.8	1.5
27773	2.6	2.1	2.3	2.8	1.6	1.4
27957	3.2	3.0	3.1	3.7	1.9	2.4
28936	1.2	1.3	1.3	1.6	0.5	0.9
28966	4.4	3.5	3.5	3.9	2.8	2.8
31089	4.5	3.8	4.2	4.2	2.0	3.3
33822	2.6	3.6	2.8	3.2	1.8	1.6
33882	3.6	3.8	3.7	3.1	1.7	2.0
33907	3.8	3.0	3.2	4.1	2.2	3.0
33984	4.7	3.8	5.6	4.0	2.3	3.2
35490	2.2	2.5	2.6	2.1	1.5	1.2
35497	2.7	3.2	2.7	2.7	1.7	1.5
37445	4.5	5.1	4.6	4.4	2.6	4.0
40044	1.6	1.3	1.3	2.4	2.0	1.6
40236	4.8	4.0	5.1	5.9	2.3	3.8
40355	5.5	4.8	5.4	4.3	2.4	2.4
40637	4.2	4.5	5.0	5.2	3.9	4.0
40809	2.9	3.2	2.7	3.7	2.5	2.2
41118	4.0	3.7	3.3	3.2	2.6	2.3
42601	3.5	3.2	4.4	3.2	2.0	2.5
Mean	3.45	3.38	3.60	3.42	2.04	2.40
Standard Deviation	1.18	1.14	1.32	1.18	0.80	0.95

E) Clinical Grading

ID	Fine Lines and Wrinkles (Eye Area)			Skin Lifting		
	Baseline	Week 4	Week 8	Baseline	Week 4	Week 8
18	5.5	5.5	5.5	4.0	4.0	4.0
841	5.0	5.0	5.0	5.0	5.0	5.0
871	7.0	7.0	7.0	5.5	5.5	5.5
1440	5.5	5.5	5.5	5.5	5.5	5.5
1566	6.0	5.5	5.5	6.5	6.5	6.5
2337	6.5	6.0	6.0	6.5	6.0	6.0
3441	6.5	6.5	6.5	6.5	6.5	6.5
3445	7.0	6.5	6.5	6.5	6.5	6.5
3894	5.5	5.5	5.5	6.0	6.0	6.0
4321	6.5	6.0	6.0	6.0	6.0	5.5
4988	6.5	6.0	6.0	6.5	6.5	6.5
5107	7.0	7.0	7.0	6.5	6.5	6.5
6217	5.0	5.0	4.5	5.0	5.0	5.0
6987	7.0	6.5	6.5	6.5	6.5	6.5
7102	5.5	5.0	5.0	5.5	5.0	5.0
7226	4.5	4.0	4.0	4.0	3.5	3.5
7767	5.5	5.0	5.0	5.5	5.5	5.5
14404	6.5	6.0	6.0	6.5	6.5	6.5
14578	7.0	7.0	7.0	6.0	6.0	6.0
15152	5.0	5.0	5.0	6.5	6.5	6.5
18766	5.0	5.0	5.0	5.0	5.0	5.0
18949	6.5	6.0	6.0	6.5	6.0	6.0
19606	6.5	6.5	6.0	6.0	6.0	6.0
19674	6.0	5.5	5.5	5.5	5.5	5.5
19735	5.5	5.5	5.5	5.0	5.0	5.0
22705	5.5	5.5	5.5	5.5	5.5	5.5
23348	7.5	7.0	7.0	7.0	7.0	6.5
23680	4.5	4.5	4.5	5.5	5.5	5.5

23758	6.0	6.0	6.0	5.5	5.5	5.5
23961	7.0	7.0	6.5	6.5	6.5	6.0
25078	6.5	6.5	6.5	5.5	5.5	5.5
26648	5.0	5.0	5.0	5.5	5.0	5.0
27773	6.0	5.5	5.5	5.5	5.0	5.0
27957	5.5	5.5	5.5	5.5	5.5	5.5
28936	5.5	5.5	5.5	5.5	5.0	5.0
28966	6.0	5.5	5.5	5.5	5.5	5.5
31089	6.0	6.0	6.0	5.5	5.5	5.5
33822	7.0	7.0	7.0	6.5	6.5	6.5
33882	7.0	6.5	6.5	6.5	6.0	6.0
33907	5.5	5.5	5.0	6.0	6.0	5.5
33984	5.5	5.5	5.0	4.0	4.0	3.5
35485	5.5	5.0	5.0	5.0	4.5	4.5
35490	5.5	5.5	5.5	5.5	5.5	5.5
35497	5.0	5.0	5.0	5.5	5.5	5.5
37445	6.5	6.5	6.5	6.5	6.5	6.5
40044	5.5	5.0	5.0	5.5	5.0	5.0
40236	6.5	6.5	6.5	6.5	6.5	6.5
40355	6.0	5.5	5.5	5.5	5.5	5.5
40637	6.5	6.5	6.5	6.5	6.5	6.5
40809	7.0	6.5	6.5	6.5	6.5	6.5
41118	6.0	6.0	6.0	5.5	5.5	5.0
42601	7.0	7.0	7.0	6.5	6.5	6.5
Mean	6.02	5.83	5.78	5.79	5.69	5.63
Standard Deviation	0.75	0.74	0.75	0.70	0.76	0.76

F) Post-Treatment Questionnaire (15 Minute)

ID	The serum is absorbed quickly.	I like the texture of the serum.	This serum has a pleasant smell.	My skin feels smoother.	My skin feels cooled.	My skin feels refreshed.	My skin feels relaxed.
18	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
841	Agree	Agree	Agree	Agree	Agree	Agree	Agree
871	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
1440	Agree	Agree	Agree	Agree	Agree	Agree	Agree
1566	Strongly Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree
2337	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
3441	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
3445	Agree	Agree	Agree	Agree	Agree	Agree	Agree
3894	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
4321	Agree	Agree	Agree	Agree	Agree	Agree	Agree
4988	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree
5107	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree
6217	Strongly Agree	Strongly Agree	Agree	Disagree	Disagree	Disagree	Disagree
6987	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
7102	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
7226	Strongly Agree	Strongly Agree	Agree	Disagree	Agree	Disagree	Agree
7667	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Agree	Agree
14404	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree
14578	Agree	Agree	Agree	Agree	Agree	Agree	Agree
15152	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
18766	Strongly Agree	Agree	Agree	Strongly Agree	Disagree	Agree	Agree
18949	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree
19606	Agree	Agree	Disagree	Agree	Disagree	Agree	Agree
19674	Agree	Agree	Agree	Agree	Agree	Agree	Agree
19735	Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree
22705	Agree	Agree	Agree	Agree	Agree	Agree	Agree

23348	Agree	Agree	Agree	Agree	Agree	Agree	Agree
23680	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree
23758	Agree	Agree	Agree	Disagree	Disagree	Agree	Agree
23961	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree
25078	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
26648	Agree	Agree	Disagree	Disagree	Agree	Agree	Agree
27773	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree
27957	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
28936	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
28966	Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree
31089	Agree	Agree	Agree	Agree	Agree	Agree	Agree
33822	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
33882	Agree	Agree	Agree	Agree	Agree	Agree	Agree
33907	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree
33984	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Disagree	Agree	Agree
35485	Agree	Agree	Agree	Agree	Disagree	Agree	Disagree
35490	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
35497	Strongly Agree	Agree	Agree	Disagree	Agree	Agree	Agree
37445	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree
40044	Agree	Disagree	Agree	Disagree	Agree	Agree	Agree
40236	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
40355	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
40637	Agree	Agree	Agree	Agree	Agree	Agree	Agree
40809	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Strongly Agree
41118	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Agree
42601	Agree	Agree	Agree	Agree	Agree	Agree	Agree

G) Post-Treatment Questionnaire (24 Hour)

ID	The serum is absorbed quickly.	I like the texture of the serum.	This serum has a pleasant smell.	My skin feels smoother.	My skin feels cooled.	My skin feels refreshed.	My skin feels relaxed.
18	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
841	Agree	Agree	Agree	Agree	Agree	Agree	Agree
871	Agree	Agree	Agree	Agree	Disagree	Agree	Disagree
1440	Agree	Agree	Agree	Agree	Agree	Agree	Agree
1566	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
2337	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
3441	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
3445	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Strongly Agree	Agree
3894	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
4321	Agree	Agree	Agree	Agree	Agree	Agree	Agree
4988	Agree	Agree	Agree	Agree	Agree	Agree	Agree
5107	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
6217	Strongly Agree	Agree	Strongly Agree	Disagree	Agree	Disagree	Agree
6987	Agree	Agree	Agree	Agree	Agree	Agree	Agree
7102	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
7226	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
7667	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
14404	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree
14578	Agree	Agree	Agree	Agree	Agree	Agree	Agree
15152	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree
18766	Strongly Agree	Strongly Agree	Disagree	Agree	Disagree	Agree	Agree
18949	Strongly Agree	Agree	Agree	Agree	Disagree	Agree	Strongly Agree
19606	Agree	Agree	Agree	Agree	Disagree	Agree	Agree

19674	Agree	Agree	Agree	Agree	Agree	Agree	Agree
19735	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
22705	Agree	Agree	Agree	Agree	Agree	Agree	Agree
23348	Agree	Agree	Agree	Agree	Agree	Agree	Agree
23680	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
23758	Strongly Agree	Agree	Agree	Agree	Disagree	Agree	Agree
23961	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree
25078	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
26648	Disagree	Disagree	Agree	Agree	Agree	Agree	Agree
27773	Agree	Agree	Agree	Agree	Agree	Agree	Agree
27957	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
28936	Agree	Agree	Agree	Agree	Agree	Agree	Agree
28966	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Agree	Agree
31089	Agree	Agree	Agree	Agree	Agree	Agree	Agree
33822	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
33882	Agree	Agree	Agree	Agree	Agree	Agree	Agree
33907	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
33984	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Disagree	Disagree	Agree
35485	Agree	Strongly Agree	Agree	Agree	Disagree	Agree	Disagree
35490	Agree	Agree	Agree	Agree	Agree	Agree	Agree
35496	Disagree	Agree	Agree	Agree	Agree	Agree	Agree
37445	Strongly Agree	Agree	Agree	Agree	Agree	Strongly Agree	Agree
40044	Agree	Disagree	Agree	Disagree	Agree	Agree	Agree
40236	Agree	Agree	Agree	Agree	Agree	Agree	Agree
40355	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
40637	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
40809	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree
41118	Agree	Strongly Agree	Agree	Agree	Disagree	Agree	Agree
42601	Agree	Agree	Agree	Agree	Agree	Agree	Agree

H) Post-Treatment Questionnaire (Week 4)

ID	My skin looks brightened.	My skin feels more hydrated.	My skin looks more youthful.	My skin tone is more even.	My skin has less wrinkles.	My eyes are less puffy.	the serum is absorbed quickly.	I like the texture of the serum.	This serum has a pleasant smell.	My skin feels smoother.	My skin feels cooled.	My skin feels refreshed.	My skin feels relaxed.
18	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
841	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree
871	Agree	Agree	Agree	Disagree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree
1440	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
1566	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Disagree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree
2337	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
3441	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
3445	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree
3894	Agree	Disagree	Disagree	Disagree	Disagree	Agree	Disagree	Disagree	Agree	Agree	Agree	Disagree	Disagree
4321	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree
4988	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
5107	Agree	Disagree	Disagree	Agree	Disagree	Disagree	Strongly Agree	Strongly Agree	Agree	Agree	Disagree	Disagree	Disagree
6217	Agree	Agree	Disagree	Disagree	Disagree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
6987	Disagree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Agree	Disagree

7102	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
7226	Strongly Agree	Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
7667	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
14404	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
14578	Agree	Agree	Disagree	Agree	Disagree	Disagree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree
15152	Agree	Agree	Agree	Agree	Disagree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
18766	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree
18949	Agree	Disagree	Disagree	Disagree	Disagree	Disagree	Agree	Agree	Agree	Disagree	Agree	Agree	Disagree
19606	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree
19674	Agree	Agree	Agree	Agree	Disagree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
19735	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Strongly Agree
22705	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
23348	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
23680	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
23758	Agree	Agree	Disagree	Agree	Disagree	Disagree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree
23961	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
25078	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Disagree	Disagree
26648	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Disagree	Disagree	Agree	Disagree	Strongly Disagree	Agree	SA	SA	SA	Agree
27773	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
27957	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
28936	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
28966	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
31089	Agree	Agree	Agree	Agree	Disagree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree

33822	Agree	Agree	Agree	Disagree	Disagree	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree
33882	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
33907	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
33984	Disagree	Disagree	Disagree	Agree	Disagree	Agree	Agree	Agree	Agree	Disagree	Disagree	Agree	Agree
35485	Agree	Agree	Agree	Disagree	Disagree	Agree	Agree	Agree	Agree	Disagree	Agree	Agree	Agree
35490	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree
35497	Agree	Disagree	Agree	Disagree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
37445	Agree	Agree	Agree	Strongly Agree	Agree	Strongly Agree	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree
40044	Agree	Disagree	Agree	Disagree	Agree	Disagree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree
40236	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
40355	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
40637	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree
40809	Agree	Strongly Agree	Agree	Agree	Disagree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree
41118	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree
42601	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree

I) Post-Treatment Questionnaire (Week 8)

ID	My skin looks brightened.	My skin feels more hydrated.	My skin looks more youthful.	My skin tone is more even.	My skin has less wrinkles.	My eyes are less puffy.	the serum is absorbed quickly.	I like the texture of the serum.	This serum has a pleasant smell.	My skin feels smoother.	My skin feels cooled.	My skin feels refreshed.	My skin feels relaxed.	Appearance of dark pigmentation around the eye area
18	Disagree	Disagree	Agree	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
841	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Agree
871	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree
1440	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
1566	Disagree	Agree	Disagree	Agree	Strongly Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree
2337	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
3441	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
3445	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree
3894	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
4321	Agree	Disagree	Agree	Disagree	Agree	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Disagree	Agree
4988	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Strongly Agree	Agree	Agree
5107	Disagree	Agree	Disagree	Disagree	Disagree	Strongly Disagree	Agree	Agree	Agree	Disagree	Disagree	Disagree	Disagree	Strongly Disagree
6217	Agree	Strongly Agree	Disagree	Agree	Disagree	Agree	Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree
6987	Agree	Agree	Disagree	Agree	Disagree	Agree	Agree	Agree	Agree	Disagree	Agree	Agree	Disagree	Agree

7102	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
7226	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Disagree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
7667	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree
14404	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
14518	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Agree	Disagree	Agree	Disagree	Disagree	Disagree
15152	Agree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
18766	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree
18949	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Strongly Agree	Disagree	Agree	Disagree	Agree	Disagree	Disagree	Disagree
19606	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Strongly Agree
19674	Agree	Agree	Disagree	Agree	Disagree	Disagree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Disagree
19735	Strongly Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree
22705	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Disagree
23348	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
23680	Agree	Agree	Agree	Agree	Disagree	Disagree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
23758	Agree	Agree	Agree	Disagree	Disagree	Disagree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Strongly Disagree
23961	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Strongly Agree
25078	Agree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Agree	Disagree	Agree
26648	Strongly Agree	Strongly Agree	Agree	Strongly Disagree	Strongly Disagree	Strongly Disagree	Agree	Strongly Agree	Disagree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Disagree
27773	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
27957	Agree	Disagree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Disagree
28936	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
28966	Agree	Strongly Agree	Agree	Agree	Disagree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree

31089	Agree	Agree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
33822	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree
33882	Disagree	Disagree	Agree	Agree	Agree	Disagree	Strongly Agree	Agree	Agree	Disagree	Disagree	Agree	Disagree	Agree
33907	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
33984	Disagree	Strongly Disagree	Strongly Disagree	Strongly Disagree	Strongly Disagree	Agree	Agree	Agree	Agree	Disagree	Strongly Disagree	Strongly Disagree	Disagree	Disagree
35485	Agree	Agree	Disagree	Agree	Disagree	Agree	Disagree	Agree	Agree	Disagree	Agree	Agree	Disagree	Agree
35490	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
35497	Agree	Disagree	Disagree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
37445	Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Agree	Disagree	Agree
40044	Disagree	Disagree	Agree	Disagree	Agree	Disagree	Agree	Agree	Agree	Agree	Disagree	Agree	Disagree	Disagree
40236	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree
40355	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Agree	Agree
40637	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree
40809	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree
41118	Agree	Agree	Agree	Disagree	Agree	Agree	Agree	Disagree	Agree	Disagree	Agree	Agree	Agree	Disagree
42601	Agree	Agree	Agree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree



Jordan DeSantis
Clinical Director



Mary Jo Gallegos
Clinical QA Specialist